China Life Private Equity

Hanbang Technology integrates R&D, production, and trade, with liquid chromatography products as the core.

Doma Biopharmaceutical is a biotechnology company focused on drug research and development. It utilizes proprietary platforms for the development of fully human monoclonal and bispecific antibodies. The company has integrated in vivo drug efficacy screening with robust clinical development expertise to enhance the efficiency of the drug development process. By streamlining these processes, Doma Biopharmaceutical aims to assist global partners in producing a diverse range of antibody-based therapeutics.

METiS Therapeutics is a biotechnology company that aims to drive therapies in a wide range of disease areas by integrating drug discovery and delivery with AI, machine learning, and quantum simulation.

Beijing Immunochina Pharmaceuticals Co., Ltd. is a clinical-stage biotechnology company focused on the research and development of chimeric antigen receptor (CAR) T-cell therapies and a lentiviral vector manufacturing platform aimed at treating malignant tumors. The company's pipeline includes therapies targeting CD19, which is prevalent in various B-lineage malignancies such as acute B-cell lymphoblastic leukemia and non-Hodgkin's lymphoma; B cell maturation antigen (BCMA) for multiple myeloma; and CD123, associated with leukemia blasts and stem cells. Additionally, Immunochina is conducting clinical studies on CAR-T cells for relapsed and refractory non-Hodgkin's lymphoma. Founded in 2015 and based in Beijing, the company also engages in the production of cell injections, cell therapy drugs, and offers services related to medical technology development and clinical research.

Beijing Sinotau International Pharmaceutical Technology Co., Ltd. is an integrated pharmaceutical group based in Beijing, China, with an additional office in Haikou. Founded in 2005, the company specializes in both generic and patented therapies, focusing on a broad range of products including radiopharmaceuticals and biopharmaceuticals. Sinotau manufactures various medications, including antibiotics, vitamins, hormones, and treatments for oncology, digestive, cardiovascular, diabetes, respiratory, and gynecological conditions, available in tablets, capsules, and granules. The company also serves the biotechnology industry by developing advanced generic drugs and offers expertise in medicinal chemical synthesis, drug analysis, pharmaceutical preparations, and drug registration, leveraging advanced monoclonal antibody technologies.

GeneQuantum Healthcare (Suzhou) Co., Ltd. is a high-tech company that focuses on the research and development of innovative Bio-therapeutics. GeneQuantum was founded in August 2013 at Suzhou Industrial Park, and has built-up a world-class bio-conjugation technology platform, focusing on developing series of next generation anti-tumor Antibody-Drug-Conjugates (ADCs) with best-in-class potential. Securing this round of financing will significantly promote the development of current ADC candidates towards IND filling in both US and China, meanwhile further expanding the company's product pipeline.

OPM Biosciences, founded in 2013 and located in Shanghai, China, specializes in the development and production of serum-free media specifically designed for culturing animal cells. The company focuses on providing innovative cell culture solutions that enhance research and production processes in the biotechnology sector. With a commitment to advancing cell culture techniques, OPM Biosciences aims to support various applications in life sciences research and biopharmaceutical development.

Harbour BioMed is a biotechnology company focused on discovering and developing therapeutics for cancer and inflammatory diseases, particularly through immuno-oncology. Established in 2016 and headquartered in Shanghai, China, the company employs two patented transgenic mouse platforms for generating fully human monoclonal antibodies and heavy chain only antibodies, enabling the creation of bispecific antibodies and other therapeutic compounds. Harbour BioMed's development pipeline includes products targeting various conditions, such as autoimmune diseases and respiratory infections. The company also licenses its antibody platforms to other firms and academic institutions via its Harbour Antibodies subsidiary. It has formed strategic collaborations with several notable organizations, including The Wistar Institute and WuXi Biologics, and maintains partnerships with various biopharmaceutical companies. With operations in Cambridge, Massachusetts, and antibody platform innovation in Rotterdam, the Netherlands, Harbour BioMed is positioned to enhance drug discovery and development across multiple global markets.

Wanka Online Inc. is a technology company based in Beijing, China, specializing in Android-based content distribution services. Founded in 2014, the company connects businesses across various industries with Android smartphone users in China. Wanka Online operates through four main segments: mobile advertising services, online video distribution services, game co-publishing services, and software maintenance services. The majority of its revenue is generated from the mobile advertising segment. The company also offers the DAPG Platform, an algorithm-driven tool that allows marketers to distribute content, including advertisements, games, and videos, effectively.

Asia Bioenergy Technologies Berhad (ABT) is a Malaysia-based technology incubation and investment holding company. The Company operates in four business segments: technology incubation, which comprises the main business segments; biofuel related products, which includes the sale of compounds for use in biofuel processes; information technology, which is engaged in the provision of information technology training and related services and equipment and corporate services, and biotechnology products, which is engaged in the provision of biotechnology products and services.